GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Quick Ratio

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Quick Ratio : 20.06 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Chongqing Genrix Biopharmaceutical Co's quick ratio for the quarter that ended in Jun. 2024 was 20.06.

Chongqing Genrix Biopharmaceutical Co has a quick ratio of 20.06. It generally indicates good short-term financial strength.

The historical rank and industry rank for Chongqing Genrix Biopharmaceutical Co's Quick Ratio or its related term are showing as below:

SHSE:688443' s Quick Ratio Range Over the Past 10 Years
Min: 0.14   Med: 5.76   Max: 28.02
Current: 20.06

During the past 5 years, Chongqing Genrix Biopharmaceutical Co's highest Quick Ratio was 28.02. The lowest was 0.14. And the median was 5.76.

SHSE:688443's Quick Ratio is ranked better than
93% of 1528 companies
in the Biotechnology industry
Industry Median: 3.49 vs SHSE:688443: 20.06

Chongqing Genrix Biopharmaceutical Co Quick Ratio Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Quick Ratio Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
0.14 0.19 5.76 2.71 21.75

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.28 28.02 21.75 23.66 20.06

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Quick Ratio

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Quick Ratio falls into.



Chongqing Genrix Biopharmaceutical Co Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Chongqing Genrix Biopharmaceutical Co's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(3031.857-55.451)/136.87
=21.75

Chongqing Genrix Biopharmaceutical Co's Quick Ratio for the quarter that ended in Jun. 2024 is calculated as

Quick Ratio (Q: Jun. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(2765.473-59.717)/134.878
=20.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Chongqing Genrix Biopharmaceutical Co Quick Ratio Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines